Page 2 - Stephenj Nicholls News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Novel drugs targets form of previously untreatable life-threatening bad cholesterol

Novel drugs targets form of previously untreatable life-threatening bad cholesterol
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

United statesNoord hollandStephenj nichollsStephen nichollsJournal of the american medical associationEuropean society of cardiology congressMonash university victorian heart instituteVictorian heart hospital at monash healthTherapeutic approachesLower lipoproteinProfessor stephen nichollsMonash universityVictorian heart instituteVictorian heartVictorian heart hospitalMonash health

Esperion Reports Second Quarter 2023 Financial Results

– Q2 U.S. Net Product Revenue Grew 49% Y/Y to $20.3 Million – – Q2 Retail Prescription Equivalents Grew 26% Y/Y; Q2 New to Brand Prescriptions Grew 28% Q/Q – – Submitted Applications for.

United statesTiffany aldrichAlexis callahanSheldon koenigStephenj nichollsKausikk rayAmerican diabetes associationExchange commissionEuropean medicines agencyDrug administrationEndocrine society meetingJournal of the american medical associationEuropean society of cardiologyProduct revenue grewPrescription equivalents grewBrand prescriptions grew

New Data At ESC Congress 2021 Shows Repatha® (evolocumab) Improves Features Of Plaque Stability In Patients With Acute Coronary Syndrome (ACS)

/PRNewswire/ Amgen (NASDAQ:AMGN) today announced positive data from the HUYGENS Phase 3 study showing that Repatha® (evolocumab) in addition to optimized.

Puerto ricoSouth australiaColl cardiolMichael strapazonTrish rowlandStephenj nichollsDavidm reeseExchange commissionEuropean unionDrug administrationMonash university victorian heart instituteWorld health organizationBeigene ltdCardiovascular therapeuticPrimary hyperlipidemiaCardiovascular outcomes trial

New Data At ESC Congress 2021 Shows Repatha® Improves Features Of Plaque Stability In Patients With Acute Coronary Syndrome

New Data At ESC Congress 2021 Shows Repatha® Improves Features Of Plaque Stability In Patients With Acute Coronary Syndrome
investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.

Puerto ricoSouth australiaColl cardiolMichael strapazonTrish rowlandStephenj nichollsDavidm reeseDrug administrationWorld health organizationBeigene ltdExchange commissionEuropean unionEuropean society of cardiologyMonash university victorian heart instituteEuropean societyCardiovascular therapeutic area

Daiichi Sankyo Europe GmbH: First-in-class cholesterol-lowering treatment NILEMDO - (bempedoic acid) tablet and its combination with ezetimibe NUSTENDI

Daiichi Sankyo Europe GmbH: First-in-class cholesterol-lowering treatment NILEMDO - (bempedoic acid) tablet and its combination with ezetimibe NUSTENDI - (bempedoic acid and ezetimibe) tablet approved in Switzerland (bempedoic acid) is the first oral, once-daily treatment approved in almost two decades to lower low-density lipoprotein cholesterol (LDL-C) for indicated patients - - Bempedoic acid and its fixed combination drug product with ezetimibe both deliver significant reductions in LDL-C when added to a statin or other lipid-lowering therapies 1,2 - Two-thirds of patients in Switzerland with very high cardiovascular risk do not achieve LDL-C target values set out by the European Society of Cardiology,

United statesWolfgang schiessl europeDaiichi sankyoDaiichi sankyo europe gmbCvds factsheetStephenj nichollsAshley hallRachamin yaelLucas schalchSwiss federation federal statistical officeNature communicationsDrug administrationExchange commissionLipid management team at esperionEuropean society of cardiologyEuropean union